Dr. Diamandis has published an opinion about EPCA2 at: http://www.clinchem.org/cgi/reprint/clinchem.2009.140061v1 Since a subscription is required, here is the gist of Dr. Diamandis’s contribution. First, he mentions that Dr. Getzenberg has published a new article about EPCA-2 (1) (subscription also required). In the Getzenberg article, Dr. Diamandis says that the claim has been dropped by Dr. Getzenberg that EPCA-2 distinguishes between organ confined and non organ confined prostate cancer. Otherwise, the Prostate article validates Getzenberg’s other previous claims about the EPCA-2 marker. The abstract is at: http://www3.interscience.wiley.com/journal/122373646/abstract?CRETRY=1&SRETRY=0
Dr. Diamandis’s Clinical Chemistry article says that according to ELISA assay principles and now demonstrated experimentally, the Getzenberg assay was incapable of measuring EPCA-2 at the levels claimed and thus, the results had could only be explained by some sort of bias.
So the story continues.
- Leman ES, Magheli A, Canon GW, Mangold L, Partin AW, Getzenberg RH. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate 2009;69:1188 –94.